Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunex -- Ignore unavailable to you. Want to Upgrade?

To: Walkingshadow who wrote (352)	7/27/1999 5:44:00 PM
From: KM	Respond to of 656

Split! Tuesday July 27, 4:02 pm Eastern Time Company Press Release SOURCE: Immunex Corporation Immunex Announces 2-for-1 Common Stock Split SEATTLE, July 27 /PRNewswire/ -- Immunex Corporation (Nasdaq: IMNX - news) today announced that its Board of Directors approved a 2-for-1 split of its common shares, in the form of a stock dividend. The record date of this stock split is August 12, 1999. ''Strong revenue growth and a promising product line-up position Immunex very well for the future,'' said David Mann, vice president, finance. ''With our prospects for the future and a number of achievements over the past two years that have increased the value of the company, the Board of Directors determined that it is appropriate to split the company's stock at this point.'' As of June 30, 1999, Immunex had approximately 81.7 million common shares outstanding. Upon completion of the split, the number of common shares outstanding will increase to approximately 163.4 million. This is the second time the common stock of Immunex has split since the company went public in 1983. The first common stock split of Immunex took place in the first quarter of 1999. The additional shares will be mailed or delivered on or about August 26, 1999, by the company's transfer agent, ChaseMellon Shareholder Services. Shareholders with questions regarding this stock split can call ChaseMellon Shareholder Services at 1-800-522-6645. Immunex is a biopharmaceutical company dedicated to developing immune system science to protect human health. The company's products offer hope to patients with cancer and inflammatory and infectious diseases. American Home Products Corporation (NYSE: AHP - news) owns a majority interest in Immunex. AHP is one of the world's largest research-based pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of prescription drugs and over-the-counter medications. It is also a leader in vaccines, biotechnology, agricultural products and animal health care. NOTE: This release contains forward-looking statements that involve risks and uncertainties, including risks associated with clinical development, regulatory approvals, patent litigation, product commercialization and other risks described from time to time in the SEC filings by Immunex and AHP respectively, including the most recently filed 10-K and 10-Q forms. For more information, please refer to www.immunex.com. SOURCE: Immunex Corporation